273.20
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Johnson Johnson stock is traded at $273.20, with a volume of 8.97M.
It is down -0.73% in the last 24 hours and up +3.20% over the past month.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
See More
Previous Close:
$275.20
Open:
$280
24h Volume:
8.97M
Relative Volume:
1.30
Market Cap:
$657.68B
Revenue:
$97.93B
Net Income/Loss:
$21.04B
P/E Ratio:
31.67
EPS:
8.6278
Net Cash Flow:
$17.80B
1W Performance:
+3.56%
1M Performance:
+3.20%
6M Performance:
+18.86%
1Y Performance:
+44.51%
Johnson Johnson Stock (JNJ) Company Profile
Name
Johnson Johnson
Sector
Industry
Phone
732-524-2455
Address
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ
Compare JNJ vs LLY, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
JNJ
Johnson Johnson
|
273.20 | 657.68B | 97.93B | 21.04B | 17.80B | 8.6278 |
|
LLY
Lilly Eli Co
|
1,417.54 | 1.26T | 72.25B | 25.28B | 10.37B | 27.78 |
|
ABBV
Abbvie Inc
|
294.89 | 521.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
MRK
Merck Co Inc
|
149.52 | 368.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
|
NVS
Novartis Ag Adr
|
160.79 | 303.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Johnson Johnson Stock (JNJ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-26 | Downgrade | Erste Group | Buy → Hold |
| Sep-02-26 | Resumed | UBS | Buy |
| May-13-26 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-08-26 | Resumed | TD Cowen | Buy |
| Jan-28-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-20-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Oct-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-23-25 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-23-25 | Upgrade | Erste Group | Hold → Buy |
| May-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Jul-23-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| May-30-24 | Resumed | Goldman | Neutral |
| Apr-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Dec-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-01-23 | Upgrade | UBS | Neutral → Buy |
| Oct-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Hold |
| May-30-23 | Resumed | Citigroup | Buy |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-14-22 | Reiterated | BofA Securities | Neutral |
| Jun-22-22 | Initiated | Daiwa Securities | Outperform |
| May-23-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-16-22 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-15-21 | Reiterated | Citigroup | Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-28-21 | Resumed | Morgan Stanley | Overweight |
| Apr-28-20 | Downgrade | UBS | Buy → Neutral |
| Apr-22-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-17-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-19 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Oct-11-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jul-12-19 | Resumed | Credit Suisse | Outperform |
| May-28-19 | Initiated | Goldman | Buy |
| Jan-23-19 | Reiterated | Barclays | Equal Weight |
| Jul-12-18 | Upgrade | Goldman | Sell → Neutral |
| Jun-27-18 | Initiated | Bernstein | Mkt Perform |
| Apr-23-18 | Reiterated | Citigroup | Neutral |
| Apr-18-18 | Reiterated | Stifel | Hold |
| Jan-24-18 | Reiterated | Stifel | Hold |
| Jan-12-18 | Reiterated | Wells Fargo | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-18-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-18-17 | Reiterated | Stifel | Hold |
View All
Johnson Johnson Stock (JNJ) Latest News
JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? - Zacks Investment Research
Johnson & Johnson (JNJ.HA) Seasonal Returns ChartYahoo Finance - Yahoo! Finance Canada
Johnson & Johnson (JNJ) Seasonal returns chart - Yahoo Finance Singapore
Johnson & Johnson (JNJ) Seasonal Returns ChartYahoo Finance - Yahoo! Finance Canada
Johnson & Johnson (JNJ) Seasonal returns chart - Yahoo Finance Australia
Does Johnson & Johnson (JNJ) Have A New Edge In Plaque Psoriasis? - Yahoo Finance
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher - 24/7 Wall St.
Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Is Johnson & Johnson Stock a Good Fit For Your Portfolio Risk? - Trefis
State Street Health Care SPDR (XLV) Adds Eli Lilly and Johnson & Johnson on Tuesday - Yahoo Finance UK
3 Unstoppable S&P 500 Stocks to Buy Before October Ends - The Motley Fool
Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings (NYSE:JNJ) - Seeking Alpha
Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Gross - The National Law Review
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Family history of heart disease drives 3 J&J scientists - Johnson & Johnson
Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery - Ophthalmology Times
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research
Johnson & Johnson (JNJ) Stock Trades At A Discount Following Its 97% Run - Yahoo Finance
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings - Zacks Investment Research
Johnson & Johnson schedules business review for December 8 - Investing.com
Johnson & Johnson schedules business review for December 8 By Investing.com - Investing.com Canada
Johnson & Johnson to hold investor business review on Dec. 8 - StreetInsider
Johnson & Johnson to Host Enterprise Business Review - Business Wire
Johnson & Johnson (JNJ) Sees $34.7 Million in Net ETF Selling on Oct. 23 - Yahoo Finance
Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)? - Zacks Investment Research
What Will Decide Johnson & Johnson Stock Over The Next Six Months? - Trefis
J&J allegedly fires its own HR manager over disability request - Human Resources Director
Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters - The Motley Fool
What Do Johnson & Johnson (JNJ) Cancer Trial Wins Mean For Its Stock? - Yahoo Finance
J&J reports promising results in three cancer studies - NJBIZ
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? - The Motley Fool
ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda - BioSpace
2 Beaten-Down Healthcare Stocks to Buy and Hold for the Next Decade - The Motley Fool
Which Healthcare ETF Is the Better Buy: State Street’s Pharma XPH or Simplify’s Mission-Driven PINK? - The Motley Fool
J&J reports 75% tumor response rate with novel prostate cancer therapy - Seeking Alpha
Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT? - The Motley Fool
Should You Invest in the iShares U.S. Healthcare ETF (IYH)? - Zacks Investment Research
Smith & Nephew and Johnson & Johnson Fail to Merge Orthopedic Businesses - marketscreener.com
Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here’s Where the Stock Could Go by 2030 - TIKR.com
Johnson & Johnson Deepens Hong Kong Commitment with Strategic Partnership to Accelerate Healthcare Innovation - BioPharma APAC
Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here’s Where the Stock Could Go by 2030 - Yahoo Finance
Johnson & Johnson reports response rate for head, neck cancer treatment (JNJ:NYSE) - Seeking Alpha
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer - GlobeNewswire Inc.
ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drug - Fierce Biotech
Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug - TipRanks
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? - The Motley Fool
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Johnson Johnson Stock (JNJ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Johnson Johnson Stock (JNJ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schmid Timothy | EVP, WW Chair, MedTech |
Sep 02 '26 |
Sale |
274.74 |
33,597 |
9,230,440 |
25,447 |
| Schmid Timothy | Officer |
Sep 02 '26 |
Proposed Sale |
274.74 |
33,597 |
9,230,440 |
0 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Sale |
263.36 |
15,000 |
3,950,400 |
194,451 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Option Exercise |
115.67 |
15,000 |
1,735,050 |
209,451 |
| Taubert Jennifer L | Officer |
Aug 17 '26 |
Proposed Sale |
263.36 |
15,000 |
3,950,418 |
0 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Option Exercise |
115.67 |
123,291 |
14,261,070 |
399,258 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Sale |
261.17 |
123,291 |
32,199,927 |
275,967 |
| Duato Joaquin | Officer |
Aug 13 '26 |
Proposed Sale |
261.17 |
123,291 |
32,199,927 |
0 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Option Exercise |
131.94 |
9,344 |
1,232,847 |
32,912 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Sale |
257.00 |
15,918 |
4,090,960 |
16,994 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):